Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Claudin-4 remodeling of nucleus-cell cycle crosstalk maintains ovarian tumor genome stability and drives resistance to genomic instability-inducing agents.
Villagomez FR, Lang J, Nunez-Avellaneda D, Behbakht K, Dimmick HL, Webb P, Nephew KP, Neville M, Woodruff ER, Bitler BG. Villagomez FR, et al. Among authors: behbakht k. bioRxiv [Preprint]. 2024 Sep 7:2024.09.04.611120. doi: 10.1101/2024.09.04.611120. bioRxiv. 2024. PMID: 39282307 Free PMC article. Preprint.
Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, Jeong AD, Guntupalli SR, Behbakht K, Gbaja V, Arnoult N, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: behbakht k. bioRxiv [Preprint]. 2023 Feb 23:2023.02.23.529773. doi: 10.1101/2023.02.23.529773. bioRxiv. 2023. PMID: 36865165 Free PMC article. Preprint.
EHMT1/2 inhibition promotes regression of therapy-resistant ovarian cancer tumors in a CD8 T cell-dependent manner.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: behbakht k. Mol Cancer Res. 2024 Aug 13. doi: 10.1158/1541-7786.MCR-24-0067. Online ahead of print. Mol Cancer Res. 2024. PMID: 39136655
Decoding the dynamic tumor microenvironment.
Clauset A, Behbakht K, Bitler BG. Clauset A, et al. Among authors: behbakht k. Sci Adv. 2021 Jun 4;7(23):eabi5904. doi: 10.1126/sciadv.abi5904. Print 2021 Jun. Sci Adv. 2021. PMID: 34088677 Free PMC article. Review.
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Cocozaki A, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: behbakht k. Mol Cancer Ther. 2024 May 8. doi: 10.1158/1535-7163.MCT-23-0613. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38714351
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Cocozaki A, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: behbakht k. Mol Cancer Ther. 2024 Jun 12:OF1-OF16. doi: 10.1158/1535-7163.MCT-23-0613. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38863225
104 results